(ZLAB) Zai Lab - Overview
Exchange: NASDAQ •
Country: China •
Currency: USD •
Type: Common Stock •
ISIN: US98887Q1040
Stock: Cancer Drugs, Autoimmune Drugs, Neurological Drugs, Infection Drugs
Total Rating 10
Risk 30
Buy Signal -1.55
| Risk 5d forecast | |
|---|---|
| Volatility | 56.8% |
| Relative Tail Risk | -6.45% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.92 |
| Alpha | -66.69 |
| Character TTM | |
|---|---|
| Beta | 0.852 |
| Beta Downside | 1.794 |
| Drawdowns 3y | |
|---|---|
| Max DD | 65.41% |
| CAGR/Max DD | -0.26 |
EPS (Earnings per Share)
Revenue
Description: ZLAB Zai Lab March 05, 2026
Zai Lab Limited is a biopharmaceutical company that develops and commercializes medical treatments across oncology, immunology, neuroscience, and infectious diseases. The companys business model relies on both in-house development and strategic partnerships.
Zai Labs commercial portfolio includes drugs like Zejula for ovarian cancer and Vyvgart for myasthenia gravis. The oncology sector is a significant focus for biopharmaceutical companies due to high unmet medical needs and market potential.
The company maintains an active pipeline in its core therapeutic areas and has numerous licensing and collaboration agreements with other pharmaceutical firms. These collaborations are common in the biopharmaceutical industry, allowing companies to share development costs and expand market reach.
Further research on ValueRay can provide detailed financial and operational data for Zai Lab Limited.
Headlines to watch out for
- Zejula sales growth impacts oncology revenue
- VYVGART market penetration drives immunology segment
- Regulatory approvals for pipeline drugs accelerate growth
- Competition from generic drugs erodes market share
- China healthcare policy shifts affect commercialization
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income: -175.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.14 > 0.02 and ΔFCF/TA 9.76 > 1.0 |
| NWC/Revenue: 131.1% < 20% (prev 188.3%; Δ -57.18% < -1%) |
| CFO/TA -0.13 > 3% & CFO -150.8m > Net Income -175.5m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.45 > 1.5 & < 3 |
| Outstanding Shares: last quarter (110.6m) vs 12m ago 8.70% < -2% |
| Gross Margin: 58.47% > 18% (prev 0.63%; Δ 5.78k% > 0.5%) |
| Asset Turnover: 39.03% > 50% (prev 33.65%; Δ 5.38% > 0%) |
| Interest Coverage Ratio: -33.25 > 6 (EBITDA TTM -158.2m / Interest Expense TTM 5.21m) |
Altman Z'' -10.89
| A: 0.51 (Total Current Assets 1.02b - Total Current Liabilities 416.2m) / Total Assets 1.17b |
| B: -2.24 (Retained Earnings -2.63b / Total Assets 1.17b) |
| C: -0.15 (EBIT TTM -173.3m / Avg Total Assets 1.18b) |
| D: -5.69 (Book Value of Equity -2.60b / Total Liabilities 456.9m) |
| Altman-Z'' Score: -10.89 = D |
Beneish M -2.65
| DSRI: 1.03 (Receivables 106.1m/89.4m, Revenue 460.2m/399.0m) |
| GMI: 1.08 (GM 58.47% / 62.94%) |
| AQI: 1.33 (AQ_t 0.07 / AQ_t-1 0.06) |
| SGI: 1.15 (Revenue 460.2m / 399.0m) |
| TATA: -0.02 (NI -175.5m - CFO -150.8m) / TA 1.17b) |
| Beneish M-Score: -2.65 (Cap -4..+1) = A |
What is the price of ZLAB shares?
As of March 23, 2026, the stock is trading at USD 18.09 with a total of 1,617,925 shares traded.
Over the past week, the price has changed by -5.09%, over one month by -8.27%, over three months by +2.15% and over the past year by -49.29%.
Over the past week, the price has changed by -5.09%, over one month by -8.27%, over three months by +2.15% and over the past year by -49.29%.
Is ZLAB a buy, sell or hold?
Zai Lab has received a consensus analysts rating of 4.50.
Therefore, it is recommended to buy ZLAB.
- StrongBuy: 7
- Buy: 4
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ZLAB price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 39.1 | 116.1% |
| Analysts Target Price | 39.1 | 116.1% |
ZLAB Fundamental Data Overview March 19, 2026
P/S = 4.5732
P/B = 2.9411
Revenue TTM = 460.2m USD
EBIT TTM = -173.3m USD
EBITDA TTM = -158.2m USD
Long Term Debt = 19.7m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 210.9m USD (from shortTermDebt, last quarter)
Debt = 224.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -455.3m USD (from netDebt column, last quarter)
Enterprise Value = 1.64b USD (2.10b + Debt 224.3m - CCE 689.6m)
Interest Coverage Ratio = -33.25 (Ebit TTM -173.3m / Interest Expense TTM 5.21m)
EV/FCF = -10.32x (Enterprise Value 1.64b / FCF TTM -158.9m)
FCF Yield = -9.69% (FCF TTM -158.9m / Enterprise Value 1.64b)
FCF Margin = -34.53% (FCF TTM -158.9m / Revenue TTM 460.2m)
Net Margin = -38.15% (Net Income TTM -175.5m / Revenue TTM 460.2m)
Gross Margin = 58.47% ((Revenue TTM 460.2m - Cost of Revenue TTM 191.1m) / Revenue TTM)
Gross Margin QoQ = 51.15% (prev 59.62%)
Tobins Q-Ratio = 1.40 (Enterprise Value 1.64b / Total Assets 1.17b)
Interest Expense / Debt = 0.61% (Interest Expense 1.36m / Debt 224.3m)
Taxrate = 21.0% (US default 21%)
NOPAT = -136.9m (EBIT -173.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.45 (Total Current Assets 1.02b / Total Current Liabilities 416.2m)
Debt / Equity = 0.31 (Debt 224.3m / totalStockholderEquity, last quarter 715.5m)
Debt / EBITDA = 2.88 (negative EBITDA) (Net Debt -455.3m / EBITDA -158.2m)
Debt / FCF = 2.87 (negative FCF - burning cash) (Net Debt -455.3m / FCF TTM -158.9m)
Total Stockholder Equity = 769.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -14.89% (Net Income -175.5m / Total Assets 1.17b)
RoE = -22.81% (Net Income TTM -175.5m / Total Stockholder Equity 769.5m)
RoCE = -21.95% (EBIT -173.3m / Capital Employed (Equity 769.5m + L.T.Debt 19.7m))
RoIC = -14.28% (negative operating profit) (NOPAT -136.9m / Invested Capital 958.4m)
WACC = 8.16% (E(2.10b)/V(2.33b) * Re(8.98%) + D(224.3m)/V(2.33b) * Rd(0.61%) * (1-Tc(0.21)))
Discount Rate = 8.98% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -66.24%
[DCF] Fair Price = unknown (Cash Flow -158.9m)
EPS Correlation: 70.92 | EPS CAGR: 11.79% | SUE: -0.39 | # QB: 0
Revenue Correlation: 97.33 | Revenue CAGR: 30.72% | SUE: -0.57 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.47 | Chg7d=-0.176 | Chg30d=-0.220 | Revisions Net=-2 | Analysts=4
EPS current Year (2026-12-31): EPS=-1.91 | Chg7d=-0.622 | Chg30d=-0.949 | Revisions Net=-6 | Growth EPS=-19.2% | Growth Revenue=+9.2%
EPS next Year (2027-12-31): EPS=-1.45 | Chg7d=-0.920 | Chg30d=-1.476 | Revisions Net=-3 | Growth EPS=+24.1% | Growth Revenue=+28.4%
[Analyst] Revisions Ratio: -1.00 (0 Up / 2 Down within 30d for Next Quarter)
P/B = 2.9411
Revenue TTM = 460.2m USD
EBIT TTM = -173.3m USD
EBITDA TTM = -158.2m USD
Long Term Debt = 19.7m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 210.9m USD (from shortTermDebt, last quarter)
Debt = 224.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -455.3m USD (from netDebt column, last quarter)
Enterprise Value = 1.64b USD (2.10b + Debt 224.3m - CCE 689.6m)
Interest Coverage Ratio = -33.25 (Ebit TTM -173.3m / Interest Expense TTM 5.21m)
EV/FCF = -10.32x (Enterprise Value 1.64b / FCF TTM -158.9m)
FCF Yield = -9.69% (FCF TTM -158.9m / Enterprise Value 1.64b)
FCF Margin = -34.53% (FCF TTM -158.9m / Revenue TTM 460.2m)
Net Margin = -38.15% (Net Income TTM -175.5m / Revenue TTM 460.2m)
Gross Margin = 58.47% ((Revenue TTM 460.2m - Cost of Revenue TTM 191.1m) / Revenue TTM)
Gross Margin QoQ = 51.15% (prev 59.62%)
Tobins Q-Ratio = 1.40 (Enterprise Value 1.64b / Total Assets 1.17b)
Interest Expense / Debt = 0.61% (Interest Expense 1.36m / Debt 224.3m)
Taxrate = 21.0% (US default 21%)
NOPAT = -136.9m (EBIT -173.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.45 (Total Current Assets 1.02b / Total Current Liabilities 416.2m)
Debt / Equity = 0.31 (Debt 224.3m / totalStockholderEquity, last quarter 715.5m)
Debt / EBITDA = 2.88 (negative EBITDA) (Net Debt -455.3m / EBITDA -158.2m)
Debt / FCF = 2.87 (negative FCF - burning cash) (Net Debt -455.3m / FCF TTM -158.9m)
Total Stockholder Equity = 769.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -14.89% (Net Income -175.5m / Total Assets 1.17b)
RoE = -22.81% (Net Income TTM -175.5m / Total Stockholder Equity 769.5m)
RoCE = -21.95% (EBIT -173.3m / Capital Employed (Equity 769.5m + L.T.Debt 19.7m))
RoIC = -14.28% (negative operating profit) (NOPAT -136.9m / Invested Capital 958.4m)
WACC = 8.16% (E(2.10b)/V(2.33b) * Re(8.98%) + D(224.3m)/V(2.33b) * Rd(0.61%) * (1-Tc(0.21)))
Discount Rate = 8.98% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -66.24%
[DCF] Fair Price = unknown (Cash Flow -158.9m)
EPS Correlation: 70.92 | EPS CAGR: 11.79% | SUE: -0.39 | # QB: 0
Revenue Correlation: 97.33 | Revenue CAGR: 30.72% | SUE: -0.57 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.47 | Chg7d=-0.176 | Chg30d=-0.220 | Revisions Net=-2 | Analysts=4
EPS current Year (2026-12-31): EPS=-1.91 | Chg7d=-0.622 | Chg30d=-0.949 | Revisions Net=-6 | Growth EPS=-19.2% | Growth Revenue=+9.2%
EPS next Year (2027-12-31): EPS=-1.45 | Chg7d=-0.920 | Chg30d=-1.476 | Revisions Net=-3 | Growth EPS=+24.1% | Growth Revenue=+28.4%
[Analyst] Revisions Ratio: -1.00 (0 Up / 2 Down within 30d for Next Quarter)